Clinical Trial Detail

NCT ID NCT04220866
Title Study of Intratumoral (IT) MK-1454 in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

head and neck squamous cell carcinoma

Therapies

MK-1454 + Pembrolizumab

Pembrolizumab

Age Groups: adult senior

No variant requirements are available.